Sorrento Therapeutics, Inc. announced Sorrento Therapeutics Mexico, a Sorrento company, has won the first tender offer by the Mexico City Municipal Government for the purchase of COVISTIX COVID-19 Virus Rapid Antigen Detection tests. COVISTIX provides a rapid and sensitive means of detecting asymptomatic and symptomatic infections caused by the currently circulating Omicron variant of SARS-CoV-2. The COVISTIX tests will be delivered this week. Sorrento is active in participating in more tender orders worldwide as governments around the world are dramatically ramping up its COVID testing and monitoring programs with the intention to make rapid testing a focus of its disease control strategy.

Sorrento is well-positioned to become a key partner in this effort given the high sensitivity and commercial availability of the COVISTIX tests.